golodirsen sold brand name vyondys medication used treatment duchenne muscular dystrophy antisense oligonucleotide drug phosphorodiamidate morpholino oligomer pmo common side effects include headache fever fall cough vomiting abdominal pain cold symptoms nasopharyngitis golodirsen indicated treatment duchenne muscular dystrophy dmd people confirmed mutation dystrophin gene amenable exon golodirsen provisionally approved approximately dmd patients amenable exon works inducing exon skipping dystrophin gene thereby increasing amount dystrophin protein available muscle common side effects include headache fever fall cough vomiting abdominal pain cold symptoms nasopharyngitis animal studies significant changes seen male reproductive system monkeys mice following weekly subcutaneous according reports obtained clinical trials pain site intravenous administration back pain oropharyngeal pain sprain ligaments diarrhea dizziness contusion flu ear infection rhinitis skin abrasion tachycardia constipation occurred elevated frequency treatment group compared placebo hypersensitivity reactions including rash fever itching hives skin irritation dermatitis skin peeling exfoliation occurred people treated renal toxicity observed animals received although renal toxicity observed clinical studies golodirsen potentially fatal glomerulonephritis observed administration antisense renal function monitored taking following single multiple intravenous infusions majority drug elimination occurs within hours intravenous administration elimination halflife golodirsen parity eteplirsen firstgeneration drug golodirsen far away curative clinical trial outcomes demonstrated drug marginal effect ameliorating dmd december golodirsen approved therapeutic use united states well countries automatically recognize decisions us food drug administration condition benefit demonstrated confirmatory clinical trial golodirsen one fdaapproved exonskipping therapy duchenne muscular dystrophy dmd although clinical benefits drug yet development golodirsen needed huge financing applicable small subset dmd patients sarepta therapeutics announced golodirsen cost parity eteplirsen another drug similar kind may high year whether patients spend much drug questioned efficacy raises concerns also accelerated approval golodirsen paved way patients early access drug time shrouded controversy number doubleblind placebocontrolled confirmatory trial ongoing resolve issues golodirsen developed collaborative research led prof steve wilton prof sue fletcher perron institute licensed sarepta therapeutics university western pivotal clinical trial golodirsen dystrophin levels increased average normal baseline normal weeks treatment drug change surrogate endpoint trial establish clinical benefit drug including changes subjects motor pharmacological assessment golodirsen include special population groups eg pregnant lactating women elderly patients concurrent disease states dmd predominantly affects male children young adults golodirsen indicated treatment pediatric patients primarily adult women elderly patients comorbidity evaluated us food drug administration fda approved golodirsen december accelerated approval application golodirsen granted fast track designation priority review designation orphan drug designation rare pediatric disease priority review httpsenwikipediaorgwikigolodirsen